The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
ADMA BIOLOGICS INC COM 000899104 13,350 3,608,171 SH   SOLE   3,608,171 0 0
AGILE THERAPEUTICS INC COM 00847L100 6,768 1,804,933 SH   SOLE   1,804,933 0 0
AIMMUNE THERAPEUTICS INC. COM 00900T107 61,474 2,990,000 SH   SOLE   2,990,000 0 0
CHIMERIX INC. COM 16934W106 2,578 472,943 SH   SOLE   472,943 0 0
CIDARA THERAPEUTICS INC. COM 171757107 7,659 1,021,148 SH   SOLE   1,021,148 0 0
ESPERION THERAPEUTICS INC. COM 29664W105 38,742 837,125 SH   SOLE   837,125 0 0
LOXO ONCOLOGY INC COM 548862101 335,909 4,188,920 SH   SOLE   4,188,920 0 0
PARATEK PHARMACEUTICALS INC COM 699374302 11,633 482,680 SH   SOLE   482,680 0 0
PERNIX THERAPEUTICS HLDGS IN COM NEW 71426V306 844 210,000 SH   SOLE   210,000 0 0
PERNIX THERAPEUTICS HLDGS INC DBCV 4.250% 4/0 71426VAK4 775 2,500,000 PRN   SOLE   2,500,000 0 0
SYROS PHARMACEUTICALS, INC. COM 87184Q107 8,183 508,565 SH   SOLE   508,565 0 0
T2 BIOSYSTEMS INC COM 89853L104 4,890 1,523,499 SH   SOLE   1,523,499 0 0
TRANSENTERIX INC. COM NEW 89366M201 7,338 10,335,819 SH   SOLE   10,335,819 0 0
VERSARTIS INC COM 92529L102 35,327 2,024,465 SH   SOLE   2,024,465 0 0
VIEWRAY INC. COM 92672L107 48,402 7,480,887 SH   SOLE   7,480,887 0 0
ZELTIQ AESTHETICS INC COM 98933Q108 0 11,985 SH   SOLE   11,985 0 0